These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 31127296)

  • 1. Fatty acid conjugation enhances potency of antisense oligonucleotides in muscle.
    Prakash TP; Mullick AE; Lee RG; Yu J; Yeh ST; Low A; Chappell AE; Østergaard ME; Murray S; Gaus HJ; Swayze EE; Seth PP
    Nucleic Acids Res; 2019 Jul; 47(12):6029-6044. PubMed ID: 31127296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Palmitic acid conjugation enhances potency of tricyclo-DNA splice switching oligonucleotides.
    Relizani K; Echevarría L; Zarrouki F; Gastaldi C; Dambrune C; Aupy P; Haeberli A; Komisarski M; Tensorer T; Larcher T; Svinartchouk F; Vaillend C; Garcia L; Goyenvalle A
    Nucleic Acids Res; 2022 Jan; 50(1):17-34. PubMed ID: 34893881
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms of palmitic acid-conjugated antisense oligonucleotide distribution in mice.
    Chappell AE; Gaus HJ; Berdeja A; Gupta R; Jo M; Prakash TP; Oestergaard M; Swayze EE; Seth PP
    Nucleic Acids Res; 2020 May; 48(8):4382-4395. PubMed ID: 32182359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Propensities of Fatty Acid-Modified ASOs: Self-Assembly vs Albumin Binding.
    Kusznir EA; Hau JC; Portmann M; Reinhart AG; Falivene F; Bastien J; Worm J; Ross A; Lauer M; Ringler P; Sladojevich F; Huber S; Bleicher K; Keller M
    Bioconjug Chem; 2023 May; 34(5):866-879. PubMed ID: 37145959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Conjugation of hydrophobic moieties enhances potency of antisense oligonucleotides in the muscle of rodents and non-human primates.
    Østergaard ME; Jackson M; Low A; E Chappell A; G Lee R; Peralta RQ; Yu J; Kinberger GA; Dan A; Carty R; Tanowitz M; Anderson P; Kim TW; Fradkin L; Mullick AE; Murray S; Rigo F; Prakash TP; Bennett CF; Swayze EE; Gaus HJ; Seth PP
    Nucleic Acids Res; 2019 Jul; 47(12):6045-6058. PubMed ID: 31076766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fatty Acid-Modified Gapmer Antisense Oligonucleotide and Serum Albumin Constructs for Pharmacokinetic Modulation.
    Hvam ML; Cai Y; Dagnæs-Hansen F; Nielsen JS; Wengel J; Kjems J; Howard KA
    Mol Ther; 2017 Jul; 25(7):1710-1717. PubMed ID: 28641935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Albumin-Binding Fatty Acid-Modified Gapmer Antisense Oligonucleotides for Modulation of Pharmacokinetics.
    Cai Y; Lou C; Wengel J; Howard KA
    Methods Mol Biol; 2020; 2176():163-174. PubMed ID: 32865790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted Delivery of Antisense Oligonucleotides Using Neurotensin Peptides.
    Nikan M; Tanowitz M; Dwyer CA; Jackson M; Gaus HJ; Swayze EE; Rigo F; Seth PP; Prakash TP
    J Med Chem; 2020 Aug; 63(15):8471-8484. PubMed ID: 32677436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the effects of chemically different linkers on hepatic accumulations, cell tropism and gene silencing ability of cholesterol-conjugated antisense oligonucleotides.
    Wada S; Yasuhara H; Wada F; Sawamura M; Waki R; Yamamoto T; Harada-Shiba M; Obika S
    J Control Release; 2016 Mar; 226():57-65. PubMed ID: 26855051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the effect of 2'-O-methyl, fluoro hexitol, bicyclo and Morpholino nucleic acid modifications on potency of GalNAc conjugated antisense oligonucleotides in mice.
    Prakash TP; Yu J; Kinberger GA; Low A; Jackson M; Rigo F; Swayze EE; Seth PP
    Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3774-3779. PubMed ID: 30342955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice.
    Prakash TP; Graham MJ; Yu J; Carty R; Low A; Chappell A; Schmidt K; Zhao C; Aghajan M; Murray HF; Riney S; Booten SL; Murray SF; Gaus H; Crosby J; Lima WF; Guo S; Monia BP; Swayze EE; Seth PP
    Nucleic Acids Res; 2014 Jul; 42(13):8796-807. PubMed ID: 24992960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis of multivalent fatty acid-conjugated antisense oligonucleotides: Cell internalization, physical properties, and in vitro and in vivo activities.
    Tanaka Y; Tanioku Y; Nakayama T; Aso K; Yamaguchi T; Kamada H; Obika S
    Bioorg Med Chem; 2023 Mar; 81():117192. PubMed ID: 36780806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and characterization of modified antisense oligonucleotides targeting DMPK in mice and nonhuman primates for the treatment of myotonic dystrophy type 1.
    Pandey SK; Wheeler TM; Justice SL; Kim A; Younis HS; Gattis D; Jauvin D; Puymirat J; Swayze EE; Freier SM; Bennett CF; Thornton CA; MacLeod AR
    J Pharmacol Exp Ther; 2015 Nov; 355(2):329-40. PubMed ID: 26330536
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conjugation of mono and di-GalNAc sugars enhances the potency of antisense oligonucleotides via ASGR mediated delivery to hepatocytes.
    Kinberger GA; Prakash TP; Yu J; Vasquez G; Low A; Chappell A; Schmidt K; Murray HM; Gaus H; Swayze EE; Seth PP
    Bioorg Med Chem Lett; 2016 Aug; 26(15):3690-3. PubMed ID: 27268307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Characterization of Hepatic Distribution and mRNA Reduction of Antisense Oligonucleotides Conjugated with Triantennary N-Acetyl Galactosamine and Lipophilic Ligands Targeting Apolipoprotein B.
    Watanabe A; Nakajima M; Kasuya T; Onishi R; Kitade N; Mayumi K; Ikehara T; Kugimiya A
    J Pharmacol Exp Ther; 2016 May; 357(2):320-30. PubMed ID: 26907624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dmpk gene deletion or antisense knockdown does not compromise cardiac or skeletal muscle function in mice.
    Carrell ST; Carrell EM; Auerbach D; Pandey SK; Bennett CF; Dirksen RT; Thornton CA
    Hum Mol Genet; 2016 Oct; 25(19):4328-4338. PubMed ID: 27522499
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrated Assessment of the Clinical Performance of GalNAc
    Crooke ST; Baker BF; Xia S; Yu RZ; Viney NJ; Wang Y; Tsimikas S; Geary RS
    Nucleic Acid Ther; 2019 Feb; 29(1):16-32. PubMed ID: 30570431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive Structure-Activity Relationship of Triantennary N-Acetylgalactosamine Conjugated Antisense Oligonucleotides for Targeted Delivery to Hepatocytes.
    Prakash TP; Yu J; Migawa MT; Kinberger GA; Wan WB; Østergaard ME; Carty RL; Vasquez G; Low A; Chappell A; Schmidt K; Aghajan M; Crosby J; Murray HM; Booten SL; Hsiao J; Soriano A; Machemer T; Cauntay P; Burel SA; Murray SF; Gaus H; Graham MJ; Swayze EE; Seth PP
    J Med Chem; 2016 Mar; 59(6):2718-33. PubMed ID: 26914862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hsp90 protein interacts with phosphorothioate oligonucleotides containing hydrophobic 2'-modifications and enhances antisense activity.
    Liang XH; Shen W; Sun H; Kinberger GA; Prakash TP; Nichols JG; Crooke ST
    Nucleic Acids Res; 2016 May; 44(8):3892-907. PubMed ID: 26945041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid Conjugates Enhance Endosomal Release of Antisense Oligonucleotides Into Cells.
    Wang S; Allen N; Prakash TP; Liang XH; Crooke ST
    Nucleic Acid Ther; 2019 Oct; 29(5):245-255. PubMed ID: 31158063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.